Investor Says Biotech Co. Hid Blood Treatment Funding Woes
By Ryan Harroff · January 5, 2023, 5:46 PM EST
Israeli biotechnology company BioLine misled the public and its shareholders about its financing shortfalls for a new blood therapy, then ultimately caused a 33% stock drop when it made moves to...
To view the full article, register now.
Try a seven day FREE Trial
Already a subscriber? Click here to login